AD

Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumabAtopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
tralokinumab
Tips and Tricks for Diagnosing & Managing Atopic Dermatitis (AD)
atopic dermatitisAtopic dermatitis is a heterogeneous, chronic inflammatory disease that affects upwards of 10% of children and 7% of adults in the United States. Despite being an incredibly common skin concern among patients, AD continues to pose diagnostic and treatment challenges to dermatologists. What are some common misconceptions about AD? AD always starts in childhood. FALSE. 25% of adults w …
atopic dermatitis
What’s New in Atopic Dermatitis
atopic dermatitisNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Adam Friedman (Professor and Chair of Dermatology who serves as Associate Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the GW Department of Dermatology) about the latest in Atopic Dermatitis (AD). Watch as he discu …
atopic dermatitis
JDD Issue Highlights | October 2021 | Special Focus: Atopic Dermatitis
ATOPIC DERMATITISWith a special focus on atopic dermatitis, the October issue of the Journal of Drugs in Dermatology features a great line up of original articles on topics ranging from topical body skincare for toning and tightening, the psychological burden associated with atopic dermatitis, to treatment of toenail onychomycosis in the US and everything in between! Straight from the JDD Editor’s desk, we sha …
ATOPIC DERMATITIS
Recalcitrant Dyshidrotic Eczema Treated With Dupilumab
eczemaThe following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens. Introduction Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c …
eczema